Neurogene, Inc. (NGNE)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$23.55-3.01%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Neurogene, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-1.35
Annual ending 2026-12-31
Revenue	—	462,500
EPS	—	-5.636
Annual ending 2027-12-31
Revenue	—	0
EPS	—	-5.225

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
EPS loss narrows toward -$5.3 or better in FY26	A primary condition in Neurogene, Inc.'s published investment case. The stated target is >= -5.31 USD per share.	Intact	EPS loss worsens beyond -5.31 USD per share in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Advancement of gene therapy pipeline and financial flexibility via debt issuance	Debt issuance in July 2026 provides financial flexibility.	Under Pressure	Pipeline development stalls or financing dries up	Qualitative: 2 consecutive earnings misses (Q1, Q2 2026) vs target of active pipeline/financing Earnings missed in Q1 and Q2 2026; $105M equity/debt issuance completed in June 2026. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Stock price sustains gains near current levels or higher	A supporting condition in Neurogene, Inc.'s published investment case. The stated target is Price remains within 0% drawdown from recent highs.	Broken	Drawdown exceeds 10% from recent highs	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-5.23

Unavailable → $-5.23 · observed estimates

FY2027 revenueUnavailable

Unavailable → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	4 / 0
2026-07-25	Unavailable	Unavailable	4 / 0
2026-07-26	Unavailable	Unavailable	4 / 0
2026-07-27	Unavailable	$0	4 / 7
2026-07-28	Unavailable	$0	4 / 7
2026-07-29	Unavailable	Unavailable	4 / 0
2026-07-30	Unavailable	$0	4 / 7
2026-07-31	Unavailable	$0	4 / 7
2026-08-01	Unavailable	Unavailable	4 / 0
2026-08-02	Unavailable	Unavailable	4 / 0
2026-08-03	Unavailable	$0	4 / 7
2026-08-04	Unavailable	Unavailable	4 / 0
2026-08-05	Unavailable	Unavailable	4 / 0
2026-08-06	Unavailable	Unavailable	4 / 0
2026-08-07	Unavailable	Unavailable	4 / 0
2026-08-08	Unavailable	$0	4 / 7
2026-08-09	Unavailable	$0	4 / 7
2026-08-10	Unavailable	$0	4 / 7
2026-08-12	Unavailable	$0	4 / 6
2026-08-13	Unavailable	$0	4 / 6
2026-08-14	Unavailable	Unavailable	4 / 0
2026-08-15	Unavailable	Unavailable	4 / 0
2026-08-16	Unavailable	Unavailable	4 / 0
2026-08-17	Unavailable	Unavailable	4 / 0
2026-08-18	Unavailable	Unavailable	4 / 0
2026-08-19	Unavailable	Unavailable	4 / 0
2026-08-20	Unavailable	Unavailable	4 / 0
2026-08-21	Unavailable	Unavailable	4 / 0
2026-08-22	Unavailable	Unavailable	4 / 0
2026-08-23	Unavailable	Unavailable	4 / 0
2026-08-24	Unavailable	Unavailable	4 / 0
2026-08-25	Unavailable	Unavailable	4 / 0
2026-08-26	Unavailable	Unavailable	4 / 0
2026-08-27	Unavailable	Unavailable	4 / 0
2026-08-28	Unavailable	Unavailable	4 / 0
2026-08-29	Unavailable	Unavailable	4 / 0
2026-08-30	Unavailable	Unavailable	4 / 0
2026-08-31	Unavailable	Unavailable	4 / 0
2026-09-01	Unavailable	Unavailable	4 / 0
2026-09-02	Unavailable	Unavailable	4 / 0
2026-09-03	Unavailable	Unavailable	4 / 0
2026-09-04	Unavailable	Unavailable	4 / 0
2026-09-05	Unavailable	Unavailable	4 / 0
2026-09-06	Unavailable	Unavailable	4 / 0
2026-09-07	Unavailable	Unavailable	4 / 0
2026-09-08	Unavailable	Unavailable	4 / 0
2026-09-09	Unavailable	Unavailable	4 / 0
2026-09-10	Unavailable	Unavailable	4 / 0
2026-09-11	Unavailable	Unavailable	4 / 0
2026-09-12	Unavailable	Unavailable	4 / 0
2026-09-13	Unavailable	Unavailable	4 / 0
2026-09-14	Unavailable	Unavailable	4 / 0
2026-09-15	Unavailable	Unavailable	4 / 0
2026-09-16	Unavailable	Unavailable	4 / 0
2026-09-17	Unavailable	Unavailable	4 / 0
2026-09-18	Unavailable	Unavailable	4 / 0
2026-09-19	Unavailable	Unavailable	4 / 0
2026-09-20	Unavailable	Unavailable	4 / 0
2026-09-21	Unavailable	Unavailable	4 / 0
2026-09-22	Unavailable	Unavailable	4 / 0
2026-09-23	Unavailable	Unavailable	4 / 0
2026-09-24	Unavailable	Unavailable	4 / 0
2026-09-25	Unavailable	Unavailable	4 / 0
2026-09-26	Unavailable	Unavailable	4 / 0
2026-09-27	Unavailable	Unavailable	4 / 0
2026-09-28	Unavailable	Unavailable	4 / 0
2026-09-29	Unavailable	Unavailable	4 / 0
2026-09-30	Unavailable	Unavailable	4 / 0
2026-10-01	Unavailable	Unavailable	4 / 0
2026-10-02	Unavailable	Unavailable	4 / 0
2026-10-03	Unavailable	Unavailable	4 / 0
2026-10-04	Unavailable	Unavailable	4 / 0
2026-10-05	Unavailable	Unavailable	4 / 0
2026-10-06	Unavailable	Unavailable	4 / 0
2026-10-07	Unavailable	Unavailable	4 / 0
2026-10-08	Unavailable	Unavailable	4 / 0
2026-10-09	$-5.70	Unavailable	5 / 0
2026-10-10	$-5.70	Unavailable	5 / 0
2026-10-11	$-5.70	Unavailable	5 / 0
2026-10-12	$-5.70	Unavailable	5 / 0
2026-10-13	$-5.70	Unavailable	5 / 0
2026-10-14	$-5.23	Unavailable	5 / 0
2026-10-15	$-5.23	Unavailable	6 / 0
2026-10-16	$-5.23	Unavailable	6 / 0
2026-10-17	$-5.23	Unavailable	6 / 0
2026-10-18	$-5.23	Unavailable	6 / 0
2026-10-19	$-5.23	Unavailable	6 / 0
2026-10-20	$-5.23	Unavailable	6 / 0
2026-10-21	$-5.23	Unavailable	6 / 0
2026-10-22	$-5.23	Unavailable	6 / 0
2026-10-23	$-5.23	Unavailable	6 / 0
2026-10-24	$-5.23	Unavailable	6 / 0

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	9	0	0
2026-06-01	9	0	0
2026-07-01	9	0	0
2026-08-01	9	0	0
2026-09-01	9	0	0
2026-10-01	10	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 10 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

EPS loss narrows toward -$5.3 or better in FY26Direct metric needs a verified mapping
Advancement of gene therapy pipeline and financial flexibility via debt issuancePublished status: Under Pressure
Stock price sustains gains near current levels or higherPublished status: Broken

Next proof point

Nov 12, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.6%Typical daily move · historical

Downside history

-52.2%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Neurogene, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk clinical development story, not an established earnings compounder. The multi-year view is watchful: management is advancing NGN-401 and has extended the cash runway, but recent performance is weak and confidence in the evidence is low.

What's priced into Neurogene, Inc.

NGNE is valued at a 47.2% premium to peers, with much of the valuation tied to future opportunity rather than current earnings. The evidence flags expensive valuation, but not the fuller combination of expensive valuation, weak results, and turbulent conditions. The model has low confidence, so the expectations gap is uncertain.

What the fundamentals likely do

Near term, losses may remain pressured as research and development spending rises to support NGN-401; net loss also increased over the cited period. Management has completed dosing in the registrational trial above its target, begun manufacturing runs intended to support a regulatory filing, and expects topline data in the second half of 2027. Two recent earnings misses and an elevated risk of another miss leave near-term execution uncertain.

What Neurogene, Inc. hinges on

The multi-year thesis hinges on NGN-401 clinical progress, trial results, and continued regulatory preparation, alongside the company’s ability to fund operations through its stated runway. A guidance cut or further earnings weakness would add risk, while stronger results and guidance from sector peers could support the broader Healthcare backdrop. These scenarios are uncertain, and the evidence snapshot gives low confidence.